A 12-week Randomized Controlled Study to compare the antidepressant efficacy of Vortioxetine and Escitalopram in patients with depressive episode

Ahana Hospitals LLP1 个研究点分布在 1 个国家目标入组 60 人开始时间: 2022年4月7日最近更新: 2022年2月7日

试验速览

阶段: 不适用
状态: 尚未招募
发起方: Ahana Hospitals LLP
入组人数: 60
试验地点: 1
主要终点: 17-item Hamilton Depression Scale (HAM-D17) done at baseline, 2nd week, 4th week and 12th weeks

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Vortioxetine is a novel antidepressant, promoted for its multi-modal actions and comparatively lesser side effects. Not many studies have compared the clinical efficacy of vortioxetine to commonly prescribed oral antidepressants. Hence in our study we intend to compare the efficacy of vortioxetine to escitalopram for a period of 12 weeks.

研究设计

研究类型: Interventional
分配方式: Random Number Table
盲法: Open Label

入排标准

年龄范围: 18.00 Year(s) 至 65.00 Year(s)（—）
性别: All

入选标准

•Patients who are meeting International Classification of Diseases 10 criteria for major depressive disorder Patients who gave informed written consent.

排除标准

•Patients with other comorbid psychiatric disorder (except major depressive disorder) Patients who were having comorbid substance dependence Patients with any other medical disorder which is confounding our inclusion diagnosis.

结局指标

主要结局

17-item Hamilton Depression Scale (HAM-D17) done at baseline, 2nd week, 4th week and 12th weeks

时间窗: 17-item Hamilton Depression Scale (HAM-D17) done at baseline, 2nd week, 4th week and 12th weeks

次要结局

CGI- severity of illness (CGI-S) and improvement scale (CGI-I) done at baseline, 2nd week, 4th week and 12th week(CGI- severity of illness (CGI-S) and improvement scale (CGI-I) done at baseline, 2nd week, 4th week and 12th week)

研究者

发起方

Ahana Hospitals LLP

申办方类型

Private hospital/clinic

研究点 (1)

Loading locations...

相似试验

撤回

4 期

Vortioxetine for MDD, Cognition, and Systemic Inflammatory BiomarkersUnipolar Major DepressionStage I, II or III Breast Cancer

NCT02637466University of Miami

已完成

4 期

Vortioxetine in Patients With Depression and Early DementiaMajor Depressive DisorderDementia

NCT04294654H. Lundbeck A/S82

已完成

4 期

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)Major Depressive Disorder

NCT02371980Takeda1,106

Unknown

4 期

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety DisorderMajor Depressive DisorderSocial Anxiety Disorder

NCT02294305The Medical Research Network40

已完成

3 期

Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive EpisodesMajor Depressive Disorder

NCT00596817H. Lundbeck A/S639